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Formation of Immune Complexes with a Tetanus-Derived
B Cell Epitope Boosts Human T Cell Responses to Covalently
Linked Peptides in an Ex Vivo Blood Loop System
Erika A. K. Fletcher,*,† Wendy van Maren,‡ Robert Cordfunke,‡ Jasper Dinkelaar,x
Jeroen D. C. Codee,x Gijs van der Marel,x Cornelis J. M. Melief,‡ Ferry Ossendorp,‡
Jan Wouter Drijfhout,‡ and Sara M. Mangsbo*,†
Enhancing T cell responses against both viral and tumor Ags requires efficient costimulation and directed delivery of peptide Ags
into APCs. Long peptide vaccines are considered favorable vaccine moieties from a clinical perspective, as they can harbor more
than one immunogenic epitope enabling treatment of a broader target population. In addition, longer peptides are not extracel-
lularly loaded on MHC class I; rather, they require intracellular processing and will thereby be presented to T cells mainly by
professional APCs, thereby avoiding the risk of tolerance induction. The drawback of peptide vaccines regardless of peptide length
is that naked peptides are not actively targeted to and taken up by APCs, and the standard nonconjugated adjuvant-peptide mix-
tures do not ensure cotargeting of the two to the same APC. We have identified a tetanus toxin–derived B cell epitope that can
mediate the formation of immune complexes in the presence of circulating Abs. In this study, we show that these immune
complexes improve both Ag uptake by APCs (blood monocytes and CD1c+ dendritic cells) and consequently improve CD8+
T cell recall responses in a human ex vivo blood loop system. The uptake of the peptide conjugate by blood monocytes is dependent
on Abs and the complement component C1q. We envision that this strategy can be used to facilitate active uptake of Ags into APCs
to improve T cell responses against pathogens or cancer. The Journal of Immunology, 2018, 201: 87–97.
D
endritic cells (DCs) are one of the most important cell
types of the immune system. They capture, process, and
present Ags to both CD4+ and CD8+ T cells, which
subsequently elicit an Ag-specific immune response. The capacity
of DCs to drive an immune response toward Ag-specific T cell
responses has spurred numerous clinical trials involving DCs in
cancer immunotherapy. To boost antitumor responses, DCs are
required to capture tumor Ags and receive sufficient activation
stimuli. One strategy has been to load autologous DCs with tumor
Ags ex vivo and activate them with cytokines before reinfusion
(1). This strategy consists of laborious and expensive ex vivo
culturing of DCs. Another strategy has been to vaccinate with one
or several short peptides derived from tumor-associated Ags. The
single-peptide vaccine is, however, strictly HLA-oriented and may
induce tolerance as CTL priming occurs without help and in
nonsecondary lymphoid organs (2–4). Vaccination using synthetic
long peptides (SLPs) has emerged as a solution that would reduce
the problem of tolerance induction as Ag presentation is steered to
APCs, as these peptides require cellular uptake and intracellular
processing (5). In addition, longer peptide stretches can harbor
multiple epitopes along with a mix of CD8 and CD4 epitopes,
enabling a more durable immune response (5). SLP vaccination
has shown promising results in two clinical trials including pa-
tients with HPV-induced cancers (6, 7). However, further im-
provements can be made in regard to enhanced uptake and optimal
stimulation of DCs. Work by ourselves and others (using Abs to
enhance Ag uptake) has revealed a potency of immune complexes
(ICs) to efficiently load DCs both in vitro and in vivo (8, 9).
Additionally, these ICs can induce DC activation because FcgR
cross-linking (10, 11) and priming of T cell responses is sub-
stantially enhanced, compared with responses when using naked
Ag (9, 12, 13). Collectively, these characteristics of Ag-specific
Abs are the reasons for the emerging idea of using them to target
tumor Ags to DCs. We have previously demonstrated that circu-
lating Ag-specific Abs can form Ag–Ab complexes to enhance
priming and expansion of CD8+ T cells in vivo after vaccination
with a haptenated Ag (13). Recently, it has been shown that tumor
Ag–specific mAbs induce T cell responses through the formation
of ICs that have the capacity to improve cross-presentation and
thereby long-lived antitumor responses (14).
To improve responses to tumor-associated Ags, one can envision
the use of B cell epitopes such as haptens, sugars, or peptides as
targets for circulating Abs to bind to. In this study, we make use of
an 18-mer peptide from tetanus toxin to which IgG, rather than
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IgM, Abs bind. Our strategy aims to improve Ag uptake by active
transportation and to promote cross-presentation. As SLPs are su-
perior compared with protein in the intracellular routing and MHC
loading (15), and as Ab–Ag complexes are stored in DCs to prolong
Ag presentation (16), the combination of these two findings support
our strategy. The identified B cell epitope (referred to as MTTE) is
derived from tetanus toxin and was identified through a library
peptide screen (17). In murine model systems, an [MTTE]3-SLP
conjugate improves DC activation as well as T cell priming in the
presence of anti-MTTE–specific Abs (17).
In this work, we further evaluate the potential clinical use of our
peptide conjugate in human blood using an ex vivo blood loop
system (18). This system includes fresh human blood in circula-
tion. By introducing our conjugates into the blood, we can study
various biological parameters ex vivo. This system has retained
intact complement activity, which allows interaction studies of




OVA-Alexa Fluor 488 (OVA) was purchased from Invitrogen, and peptide
conjugates were made with various SLPs (Table I). This was performed
through maleimide coupling (of the MTTE/ETTM peptides) and copper-
free click chemistry (free SLP or AFKSKACB-Alexa Fluor 488) as de-
scribed in (17) using a model SLP. In short, three copies of the MTTE or
ETTM peptide (ETTM is a scrambled MTTE control peptide, for all se-
quences see Table I), C-terminally extended with a spacer sequence (see
Table I), are coupled to a core structure (for chemical structure see Ref.
17). A subsequent peptide (SLP or similar) that includes an azide group is
coupled to the [MTTE]3-core molecule to end up with the final peptide
conjugates used in this study. Rabbit anti-MTTE (raMTTE) Abs were
made by immunization of rabbits using the peptide MTTE conjugated to
tetanus toxoid (TTd) administrated in CFA (prime) and IFA (boost). From
isolated serum, Abs were purified using a protein G column. A protein G
fraction of rabbit anti-OVA (raOVA) Abs were used together with OVA
(Worthington Biochemical, Lakewood, NJ). FcgR-blocking Abs were as
follows: anti-CD16 (Clone 3G8), anti-CD32 (Clone 7.3), and anti-CD64
(Clone 10.1) were obtained from Ancell. EGTA was purchased from
Sigma-Aldrich. Compstatin (AcICV(1MeW)QDWGAHRCT) (19) was a
kind gift from Prof. J.D. Lambris (University of Pennsylvania, School of
Medicine). The C1q Ab (Clone JL-1) was purchased from Hycult Biotech.
TetaQuin was purchased from Sanquin (Netherlands) and TTd from the
Serum Institute (Denmark).
Hybridoma cell lines producing mouse anti-MTTE IgG1 and IgG2a were
made by conjugating FIGITELKKLESKINKVFC-amide to keyhole limpet
hemocyanin and through immunization of AIP-3 mice. When sufficient
IgG1 and IgG2a titers were established, isolated spleen cells were fused
with NS-1 myeloma cells. Primary clones and sub clones were analyzed
for reactivity and two clones (one IgG1 and one IgG2a clone) were chosen
for further Ab isolation. To isolate Abs, the hybridomas were cultured in
CELLine 1000 bioreactors (Integra). The medium compartment contained
DMEM/F-12 with 1% penicillin/streptomycin and 5% FBS (Ultra Low
IgG FBS from Invitrogen), and the cell compartment contained DMEM/F-
12 with 1% PEST, 2.5% FBS (Ultra Low IgG FBS from Invitrogen), and
medium with high glucose (17.3 mM glucose and L-glutamine 2.5 mM).
Harvested supernatants were spun down at 2500 rpm for 5 min and frozen
at 280˚C. Abs were purified on a protein G column (Capra Science).
Ag–Ab complex formation
Ag–Ab complexes were preformed in vitro by incubating Ag and Ab at
37˚C for 30 min in serum-free medium. The final concentrations in blood
were, unless otherwise stated, OVA (23 nM), raOVA (333 nM), [MTTE]3-
Alexa Fluor 488 (8 nM), and raMTTE (195 nM). The preformed com-
plexes were stored at 4˚C overnight before they were used in blood loop
experiments.
Blood loop assay
Blood from healthy donors was taken in an open system and immediately
mixed with the anticoagulant Lepirudin (Refludan) at the final concentration
of 50 mg/ml. All materials in direct contact with the blood were surface
heparinized with a heparin-conjugate from Corline AB (Sweden). Blood
and conjugates were applied to heparinized polyvinyl chloride tubings
from Corline, and the loops were sealed using specialized metal connec-
tors. The blood loops were rotated on a wheel within a 37˚C incubator.
Blocking analyses were performed by incubating blood with blocking Abs
(50 mg/ml), peptides (100 mg/ml), EGTA (5 mM), EDTA (2.5 mM), or
Compstatin (10 mM) at 37˚C for 10 min before adding the conjugates.
Sampling was performed throughout the experiment, and sampled blood
was immediately mixed with EDTA to the final concentration of 10 mM.
The platelets were counted at 0, and at the end time point, Coulter AcT
Diff Hematology Analyzer was used to ensure that coagulation had not
occurred during the experimental procedure and as a response to the re-
agents added. Plasma was collected and stored at 280˚C.
FACS analysis
Whole blood was stained with Abs purchased from BioLegend: anti-CD19
(Clone HIB19), anti-CD14 (Clone M5E2), anti-CD66b (Clone G10F5),
CD1c (Clone L161), CD11c (Immunotech), CD123 (Clone 6H6), anti-
CD16 (Clone 3G8), anti-CD32 (Clone 7.3), anti-CD64 (Clone 10.1),
CD3 (clone UCHT1), CD4 (Clone OKT4), CD8 (Clone SK1), IFN-g (Clone
4S.B3), and TNF-a (clone MAb11). For the detection of CMV-specific
T cells, the iTAg Tetramer- HLA-A*0201 CMV PP65 (NLVPMVATV)
from MBL International was used. A rabbit anti–Alexa Fluor 488 poly-
clonal Ab (Invitrogen) and trypan blue (Life Technologies) were used to
quench the cell surface fluorescence. The RBCs were lysed using FACS
lysing solution (BD Biosciences), the cells were analyzed using FACS
Canto II (BD Biosciences), and the cell populations were gated using
FlowJo (Tree Star).
Intracellular staining
The intracellular staining of IFN-g and TNF-a was performed by adding
Brefeldin A (Sigma-Aldrich) after 2 h of circulation of conjugates in the
blood loop system. The experiment was terminated after another 4 h, as
described for the blood loop system above. Surface markers were stained
in whole blood prior to lysis of RBCs (BD Biosciences). The cells were
washed once before permeabilization for 10 min at room temperature
using Perm/Wash Buffer (BD Biosciences). The cells were stained for
IFN-g and TNF-a for 30 min at 4˚C in the dark and subsequently washed
in PBS with 1% BSA and 3 mM EDTA (Sigma-Aldrich).
Detection of circulating anti-OVA and anti-MTTE IgG Abs
The anti-OVA, antitetanus, and anti-MTTE IgG titers in donor plasma were
evaluated with an in-house ELISA. Plates (3590; Corning) were coated with
either OVA (5 mg/ml) (Sigma) or TTd (5 mg/ml) diluted in coating buffer
(Carbonate-Bicarbonate Buffer; Sigma-Aldrich) and Streptavidin Plates
(Thermo Fisher) were coated with MTTE-Biotin or ETTM-Biotin (1 mM)
diluted in PBS overnight at 4˚C. The plates were blocked with PBS (1%
BSA and 0.05% Tween) and washed with PBS (0.05% Tween). The
plasma samples were incubated on the plates for 2 h at room temperature.
The circulating Abs were detected using a rabbit a-human IgG HRP–
conjugated Ab (polyclonal; diluted 1:4000) and tetramethylbenzidine
(Dako). The reaction was stopped with 1 M H2SO4, and the absorbance
was read at 450–570 nm using an EMax Precision Microplate Reader
(Molecular Devices). The results were analyzed using SoftMax version
2.35 (Molecular Devices). The detection of IgG isotypes and IgM were as
described above with the following exceptions: the plates were blocked
with PBS (10% BSA and 0.05% Tween), and the HRP-conjugated Abs
were anti-IgG1 (Clone HP6070; diluted 1:500), anti-IgG2 (Clone HP6014;
diluted 1:250), anti-IgG3 (Clone HP6047; diluted 1:250), and anti-IgG4
(Clone HP6023; diluted 1:500) from Thermo Fisher and anti-IgM from
Dako (polyclonal; diluted 1:1000).
Ethical considerations
Blood sampling and diphtheria, tetanus, and pertussis (DTP) vaccination of
healthy volunteers was approved by the local ethical committee. In short, an
18G gauge needle attached to heparinized tubing was used to draw blood.
The blood was collected in a 50 ml surface heparinized tube and subse-
quently transferred to the loop tubing and then set to rotate as described
above.
The DTP vaccination was performed by routine personnel at the hospital
using a standard vaccine mixture.
Statistical analysis
Statistical analyses were performed using GraphPad Prism version 7.02
software (GraphPad software). Statistical analysis was calculated with
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either Friedman test with Dunn correction or the Wilcoxon signed-rank test:
*p , 0.05, **p , 0.01, ***p , 0.005.
Results
The tetanus-epitope targeting approach is superior to naked
peptides in boosting recall responses of NLV- and GIL-specific
CD8+ T cells in human whole blood
With the aim to use Ag-specific Abs to improve targeting of
tumor Ags to DCs, a peptide conjugate was constructed, linking
an SLP with a B cell epitope. The B cell epitope is a peptide
derived from the tetanus toxin protein. To evaluate the interaction
of the conjugate with circulating antitetanus Abs where also
complement is active, an ex vivo whole blood loop assay was
used. In the loop assay, freshly isolated blood from healthy
donors is set to rotate in loop-formed surface heparinized
polyvinyl chloride tubings to mimic natural blood circulation. To
establish if the tetanus epitope (referred to as MTTE) can fa-
cilitate T cell priming of a selected epitope, a conjugate (referred
to as [MTTE]3-NLV) consisting of an SLP containing a CMV-
derived CD8 epitope (NLVPMVATV) (Fig. 1A, Table I) was
synthesized. The [MTTE]3-NLV conjugate induced IFN-g and
TNF-a recall responses of NLV-specific CD8+ T cells in blood
from donors that were both CMV and HLA-A*0201 positive
(Fig. 1B). When comparing the naked peptide and the conju-
gate, it is possible to achieve similar responses with naked
peptides, but this requires around 100-fold more peptide than
conjugate (Fig. 1C). The [MTTE]3-NLV conjugate also contains
a CD4+ epitope (ARNLVPMVATV) (20); however, no recall
responses were seen in CD4+ T cells, most likely explained by
the donors’ HLA-DRB5–negative profile (data not shown).
To determine if the MTTE sequences can enhance T cell
responses to alternative epitopes than the NLV epitope, we
made MTTE conjugates with an influenza-derived CD8+ epitope
(GILGFVFTL) in a longer peptide stretch (See Table I). These
conjugates also induced IFN-g and TNF-a recall responses of
GIL-specific CD8+ T cells in blood from an HLA-A*0201–
positive donor (Fig. 1D).
The conjugation of at least three MTTE sequences to an SLP is
required to boost IFN-g recall responses of NLV-specific CD8+
T cells in human whole blood
ICs can have an adjuvant effect and aid T cell priming regardless
if conjugated to an Ag or not; we therefore investigated if the
recall responses induced by [MTTE]3-NLV relied on the con-
jugation of the Ab targeting sequence ([MTTE]3) or if the
[MTTE]3 and SLP induced T cell recall responses as separate
entities. The conjugation of the SLP (NLV) with the [MTTE]3
epitope was required for boosting an IFN-g recall response, as
the response was absent when incubating the two unconjugated
entities in the same sample (Fig. 2A). In addition, the conju-
gation of three MTTE sequences was superior in T cell acti-
vation, as conjugates carrying one or two MTTE per SLP did
not induce as high NLV-specific IFN-g release by T cells
(Fig. 2B). To determine if the [MTTE]3-NLV conjugate re-
quires circulating human anti-MTTE IgG Abs to induce an IFN-g
recall response, the conjugate was titrated and compared with a
control substance ([ETTM]3-NLV). The control substance has a
scrambled MTTE peptide sequence (referred to as ETTM),
which eliminates the anti-MTTE Ab binding site, and donors do
not have IgG Abs detectable to this sequence (determined by
ELISA, data not shown). The [MTTE]3-NLV conjugate, but not
the [ETTM]3-NLV conjugate, boosted recall responses of NLV-
specific CD8+ T cells in a concentration-dependent manner
(Fig. 2C). In agreement, the importance of the MTTE sequence
was evident by the fact that an IFN-g response was reduced in a
donor recently vaccinated with DTP when preincubating the
blood with a “cold” conjugate without the SLP (NLV) sequence
([MTTE]3) but not with a cold [ETTM]3 conjugate, in which the
aim of the preincubation was to consume circulating anti-MTTE
IgG Abs (Fig. 2D). Supportively, a mouse anti-MTTE IgG2a Ab
could enhance a weak IFN-g recall response induced by
[MTTE]3-NLV in a donor that had not recently been vaccinated
(Fig. 2E).
The tetanus-epitope targeting strategy improves Ag uptake
into human blood monocytes and CD1c+ DCs in an
Ab-dependent manner
As the NLV recall response is enhanced when conjugating the
MTTE sequences to the SLP (NLV) sequence, we next analyzed
which blood immune cells take up the conjugates. This was per-
formed by conjugating the three MTTE sequences to an Alexa Fluor
488–labeled peptide, a conjugate hereafter named [MTTE]3-AF488.
As illustrated in Fig. 3A, [MTTE]3-AF488 bound to blood mono-
cytes, and this binding was enhanced in some donors by pre-
incubating the conjugate with raMTTE IgG Abs (preformed ICs).
Preformed ICs, but not [MTTE]3-AF488 alone, bound B cells
(Fig. 3A). In contrast, Ab-complexed [MTTE]3-AF488 conju-
gates did not bind granulocytes (data not shown). No conjugate
interaction was seen on FcgR-negative cells like T cells (data not
shown). The data resemble the uptake pattern of the model Ag
OVA when using Alexa Fluor 488–labeled OVA alone or as pre-
formed complexes using raOVA IgG, with the difference of ad-
ditional uptake by granulocytes (Supplemental Fig. 1A). By
quenching the surface-bound [MTTE]3-AF488 with an anti–Alexa
Fluor 488 Ab, the cellular localization (extra- or intracellular) of
the conjugate was determined. [MTTE]3–AF488 complexes (with
both circulating and rabbit Abs) were internalized by monocytes,
whereas B cells partially internalized and partially adhered to
rabbit Ab–complexed [MTTE]3-AF488 conjugates (Fig. 3B), re-
sembling the uptake pattern of OVA (Supplemental Fig. 1A). The
fluorescent signal by monocytes was maintained over time,
whereas the signal by B cells was lost over time (Fig. 3B), sug-
gesting that B cells initially bind complexes without actively in-
ternalizing them, possibly acting as transporters of the conjugates.
Blood monocytes also internalized the conjugate in the absence
of raMTTE IgG Abs (Fig. 3A, 3B). To determine if this uptake
was dependent on circulating human anti-MTTE IgG Abs, the
conjugate was titrated and compared with the control conju-
gate [ETTM]3-AF488, to which the donors lack IgG Abs
against (data not shown). Monocytes specifically internalized
the [MTTE]3-AF488 conjugate, but not the ([ETTM]3-AF488
conjugate, illustrating the requirement of circulating anti-
MTTE Abs (Fig. 3C, 3D). In agreement, the circulating hu-
man anti-MTTE IgG levels were reduced in plasma samples
taken from executed loop experiments (seen in four out of nine
donors) in the presence of [MTTE]3-AF488 (data not shown);
this was also noted when using OVA in the loop system (data
not shown). Consistently, raMTTE IgG Abs enhanced mono-
cyte uptake of [MTTE]3-AF488 but not [ETTM]3-AF488
(Supplemental Fig. 1B). The uptake of [MTTE]3-AF488 was
analyzed using monocytes, as they are abundant APCs in whole
blood. To confirm that professional APCs also take up the
conjugates, uptake by blood DCs was confirmed by staining for
CD1c+CD11chighCD123low and CD192 cells (Supplemental
Fig. 2) (21). Blood DCs take up [MTTE]3-AF488 in a similar
manner to monocytes (Fig. 3E).
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[MTTE]3-AF488 uptake by monocytes and IFN-g recall
responses of NLV-specific CD8+ T cells are partly dependent
on the classical complement pathway
The uptake mechanism of [MTTE]3-SLPs by monocytes was in-
vestigated by blocking FcgR, which are known to facilitate uptake
of Ag–Ab complexes. By individual blocking of CD16, CD32, and
CD64, the uptake of [MTTE]3-AF488 by monocytes was not af-
fected (data not shown). Furthermore, to eliminate any redundancy,
CD16, CD32, and CD64, all expressed by blood monocytes
(Supplemental Fig. 3), were all blocked at once, and as a conse-
quence, monocytes slightly increased their uptake of the conjugates
(data not shown). To determine the route of uptake, the complement
system was blocked with the chelating agents EDTA and EGTA.
EGTA blocks the classical pathway (CP), whereas EDTA blocks
both the classical and the alternative pathway (AP) (22, 23). The
uptake of [MTTE]3-AF488 by monocytes was abolished by both
EDTA and EGTA addition, but not by specifically blocking the AP
with the C3-specific inhibitor Compstatin, indicating a role of the
CP in the uptake mechanism (Fig. 4A). Consistently, EDTA
and EGTA, but not Compstatin, reduced the percentage of IFN-g–
producing NLV-specific CD8+ T cells in response to [MTTE]3-NLV
(Fig. 4B). In the mouse, C1q of the CP is crucial for the presentation
FIGURE 1. The peptide-conjugates with NLV- and GIL- CD8+ epitopes boost IFN-g and TNF-a recall responses of epitope-specific CD8+ T cells in human
whole blood. The peptide-conjugate [MTTE]3-NLV (A), containing the CD8 epitope pp65(NLV) from CMV, was incubated at a final concentration of 120 nM
in human whole blood from HLA-A*0201+ and CMV+ healthy donors in a circulating blood loop assay. After 2 h, Brefeldin Awas added, and after a total of
6 h, aliquots were harvested and stained for T cell markers, tetramer HLA-A*0201 CMV pp65 (NLVPMVATV), and intracellular IFN-g and TNF-a and analyzed
with flow cytometry (B). The IFN-g release in response to [MTTE]3-NLV was compared with up to ∼100-fold higher SLP (NLV) concentration [(C), n = 3]. The
peptide-conjugate [MTTE]3-GIL (480 nM) containing the CD8 epitope GIL from influenza (GILGFVFTL) was run as described above [(D), n = 1].
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of complexed OVA (24) also in cross-presenting DCs (25), and the
uptake of complexed OVA by human monocytes is C1q-dependent
in human whole blood (Supplemental Fig. 4). To determine if C1q
is involved in the uptake of [MTTE]3-AF488 by human monocytes,
blood was preincubated with a C1q binding peptide with the aim to
block C1q activity. The uptake of [MTTE]3-AF488 was reduced
when blocking the CP component C1q (Fig. 4C). Interestingly,
the C1q binding peptide block completely abolished the IFN-g–
producing NLV-specific CD8+ T cells in response to [MTTE]3-NLV
(Fig. 4D). Additionally, an anti-C1q–blocking Ab also blocked the
uptake of [MTTE]3-AF488 by monocytes and reduced the per-
centage of IFN-g–producing NLV-specific CD8+ T cells in response
to [MTTE]3-NLV in some donor blood (data not shown).
The analyzed blood donors have circulating IgG Abs against
the MTTE peptide
As the conjugate uptake by monocytes and the induction of recall
responses is dependent on circulating Abs, the IgG versus IgM
profile was investigated in an in-house ELISA. The setup was
assessed using the IgG preparation of TetaQuin (Sanquin, Neth-
erlands; isolated and pooled IgG preparation from donors with
established high titers against TTd) and all four IgG isotypes,
IgG1–4, were detected against TTd (Fig. 5A). In plasma, from a
randomly selected donor pool that had not recently been vacci-
nated with DTP, MTTE-specific IgG, but not IgM, Abs were de-
tected (Fig. 5B). The OD values varied greatly between donors,
but in all donors, the IgG OD values were above a cutoff of 1.1 of
MTTE/ETTM fold change, whereas there was no positive score
for the IgM OD value with this selection criteria. Circulating
antitetanus IgG1 and IgG4, but not IgG2 and IgG3, Abs were
detected (data not shown). This is consistent with published data
of IgG isotype profiling post-DTP vaccination (26). Because the
induction of T cell recall responses was found Ab-dependent
(Fig. 2), the next step was to evaluate if a tetanus booster vacci-
nation could enhance MTTE-specific IgG titers and conjugate
induced T cell responses against the linked T cell epitope.
A tetanus vaccination boosts MTTE-specific IgG1 levels and
enhances IFN-g recall responses of NLV-specific CD8+ T cells
Although the recall responses induced by [MTTE]3-NLV can be
enhanced by mouse anti-MTTE Abs, this approach would require
an additional clinical development of a human IgG with a MTTE
specificity to the current vaccine program. Therefore, a tetanus
vaccination booster was investigated as a way to increase circu-
lating anti-MTTE Abs, with the ultimate aim to enhance the
recall response. The vaccination enhanced anti-MTTE IgG titers
(median 1:2400 before and 1:12,800 after vaccination), but not
IgM titers, in healthy volunteers (Fig. 6A, Table II). Furthermore,
the vaccination enhanced the titers of anti-MTTE IgG1 Abs
(median 1:10 before and 1:100 after vaccination) in all donors and
IgG4 in one out of six donors, whereas IgG2 and IgG3 were un-
detected (Fig. 6B, Table II). Additionally, the vaccination greatly
enhanced the recall responses induced by [MTTE]3-NLV in blood
from the two donors that were HLA-A2+CMV+ (Fig. 6C). Before
donors were given the DTP vaccination, an addition of mouse
anti-MTTE IgG2a into the loops enhanced the responses (Fig. 2E),
whereas after the DTP vaccination, IgG2a and IgG1 decreased the
responses (data not shown).
Discussion
T cells and their role in the control of viral diseases and malig-
nancies are well recognized. Novel cancer therapies, such as
checkpoint inhibitors, rely on the tumor to release Ags and the
checkpoint inhibitors to release the break on these activated cells.
For many patients, it is also of importance to boost both frequencies
of tumor-reactive T cells and their activation through delivery of Ag
material. Many existing therapeutic vaccines are hampered by poor
Ag delivery, tolerance induction, Ag competition, and HLA lim-
itations, among other pitfalls (2, 15, 27). In this study, we have
focused on improving SLPs by IC formation, which is one of the
most efficient pathways of delivering Ags and activating T cells.
Key publications demonstrate both the efficiency of complexes to
load APCs with Ag and the adjuvant capacity through stimulation
of activating FcgR (8, 9, 13). Diseases linked to ICs (28, 29) and
the T cell–mediated tissue destruction also indicate the potential
of the strategy and the importance of choosing the right viral/
tumor Ags to be combined with the strategy.
We have previously identified an 18-mer B cell epitope (MTTE)
from tetanus toxin (17). For the current study, we use conjugates of
MTTE attached to an Alexa Fluor 488–labeled peptide or a model
T cell epitope to study cellular distribution and the mode of action
of the vaccine strategy in a human whole blood assay. The in-
teraction of Ag–Ab complexes with human whole blood was
analyzed using an ex vivo blood loop assay with intact comple-
ment cascade systems. Both the model Ag OVA and our Alexa
Fluor 488–labeled conjugate ([MTTE]3-AF488) rapidly bound to
monocytes and B cells in blood. Outer surface quenching of the
fluorophore indicates that the Ag was internalized in monocytes,
whereas B cells acted more to retain Ag in circulation without
ingesting it. Preformed complexes could improve uptake in most,
but not all, donors of both model systems. As B cells only express
Table I. Peptide sequences
Abbreviations Sequence
[MTTE]3-NLV [FIGITELKKLESKINKVF-AAKYARVRAKC]3 - CORE
LINKER- SLP (NLV)a
[ETTM]3-NLV [EKLINKLSKIFKGTIEVF-AAKYARVRAKC]3 - CORE
LINKER - SLP (NLV)





C1q binding peptide CEGPFGPRHDLTFCW
Control peptide FPLRAPTFFVRRTIG
aThe underlined MTTE sequence and the core linker are described in Ref. 17.
bO Lys(biotin).
cCD4 epitopes are underlined, and CD8 epitopes are bolded.
B, amide; Z, aminohexane acid.
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the inhibitory CD32b, whereas monocytes express CD32a/c or
CD16a and/or complement receptors, Ag uptake is likely medi-
ated by these activating low-affinity FcR or innate receptors. The
uptake of fluorescent [MTTE]3-AF488 was analyzed using human
monocytes as an abundant type of APCs in whole blood. To
confirm uptake by professional APCs, whole blood was stained
for DCs (CD11highCD123lowCD1c+ and CD192) (21), which were
found able to take up [MTTE]3-AF488. Importantly, uptake by
DCs was similar to monocytes, suggesting that this in vivo DC-
loading technology can be useful for many types of Ags.
The prospect of the conjugate as a vaccination strategy relies on
its ability to prime or activate SLP-specific T cells. To study T cell
activation, we made use of a recall assay using CMVas a model Ag.
Blood from HLA-A*0201+ and CMV-positive donors was used to
assess how cytotoxic T cells respond to our model conjugate
([MTTE]3-NLV) as compared with control conjugates. Both IFN-g
and TNF-a responses were induced by NLV-specific T cells in
response to our novel peptide conjugate (after only 6 h of incu-
bation), whereas control conjugates failed to induce T cell acti-
vation. Aggregated data of various concentrations of conjugates
FIGURE 2. The conjugation of at least three MTTE sequences per SLP is required to boost IFN-g recall responses of Ag-specific CD8+ T cells in human
whole blood. The peptide-conjugate [MTTE]3-NLV (Fig. 1A) was incubated at a final concentration of 120 nM in whole blood from HLA-A*0201
+ and
CMV+ healthy donors in a circulating blood loop assay. After 2 h, Brefeldin A was added, and after a total of 6 h, cells were stained for tetramer HLA-
A*0201 CMV pp65 (NLVPMVATV) and intracellular IFN-g and analyzed with flow cytometry. [MTTE]3-NLV in a conjugated form was compared with
the two separate entities ([MTTE]3 + SLP [NLV]) [(A), n = 5 donors run at separate occasions, and the lines represent the mean]. IFN-g responses induced
by conjugates with one, two, or three MTTE sequences were compared, and the percentage of IFN-g+ NLV–specific cells induced by conjugates with one,
two, or three MTTE is shown [(B), n = 4 donors run at separate occasions]. IFN-g responses induced by [MTTE]3-NLV were compared with that of a
conjugate containing a scrambled MTTE sequence [ETTM]3-NLV, showing the mean and SD [(C), n = 2 donors run at separate occasions]. The cold
conjugate without an SLP ([MTTE]3 or the scrambled control conjugate [ETTM]3) was preincubated in the blood (from a donor that mounts a strong T cell
response against [MTTE]3-NLV) for 10 min before [MTTE]3-NLV was added and analyzed as described above [(D), n = 1]. The IFN-g response of a donor
that mounts a poor T cell response against [MTTE]3-NLV, was analyzed with the addition of a mouse anti-MTTE IgG2a Ab at the final concentration of
40 mg/ml [(E), one representative donor out of three]. The data were analyzed with Friedman test with Dunn correction. **p , 0.01.
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versus SLPs alone demonstrate that approximately a 100-fold less
conjugate (equimolar range) was required to induce similar IFN-g
responses, which may reflect both the increase in active Ag uptake
along with an optimized intracellular processing pathway for
cross-presentation induced by ICs (9, 16). The more potent recall
responses associated with the MTTE-linked T cell epitopes were
demonstrated to be not only applicable to the CMV epitope, as a
conjugate with the influenza-derived epitope could boost IFN-g
release of influenza-specific T cells.
The tetanus-derived 18-mer peptide (MTTE) most likely creates
a scenario in which the Abs are restricted to bind a single antigenic
determinant, similar to mAbs; we therefore investigated whether
one, two, or three MTTE sequences were optimal for T cell ac-
tivation. It was clear that at least three B cell epitopes were required
for T cell activation to occur, most likely due to formation of a
complex rather than merely a monomeric Ab–carrying Ag, which
should not have the capacity to trigger FcgR activation or trigger
complement activation. Based on previous data, both Ag-loading
and adjuvant effects through Fcg/innate receptor stimulation are
of importance in providing T cell priming/activation (8, 9). To test
if the T cell activation induced by [MTTE]3-NLV was only a result
of the adjuvant part, the complexes and the T cell Ag were pro-
vided as a one-plus-one combination rather than one entity. This
did not provide the same magnitude of T cell responses, demon-
strating the need for linked adjuvant/Ag for optimal delivery/
activation. Conjugation of the adjuvant and the Ag is most
likely necessary for the improved loading of the Ag into the APCs
and thereby facilitating enhanced T cell activation. In a setting
where de novo priming plays a greater role than in recall settings,
a role for the adjuvant (Fc stimulatory effect) can also be of im-
portance. Additionally, conjugation of adjuvant and Ag is of im-
portance for ensuring Ag uptake and activation of the same APC,
something that is not ensured when long peptides are provided in,
for example, mineral oil depots.
Whole anti-TTd isotype profiling has shown that IgG1 and IgG4
are prevalent isotypes toward the protein. A tetanus vaccine boost
increased the donors’ IgG titers, without the induction of IgM,
against the MTTE epitope and promoted an increase in T cell
activation in response to the [MTTE]3-NLV model conjugate.
The MTTE epitope has a partial overlap with a universal CD4
FIGURE 3. The uptake of [MTTE]3-AF488 by human blood monocytes and B cells is Ab dependent. Alexa Fluor 488–labeled [MTTE]3-SLP,
([MTTE]3-AF488), raMTTE, or in vitro preincubated [MTTE]3-AF488 and raMTTE (preformed IC) were incubated in blood from healthy donors in a
circulating blood loop assay. After 1 h (and 4 h where indicated), aliquots were harvested and stained for monocytes (CD14+CD192) and B cells (CD19+
CD142). The uptake was analyzed with flow cytometry, and the fold change in mean fluorescence intensity (AF488) postloop/preloop (0 time point) is
presented in [(A), n = 6]. The surface-bound AF488 (1 and 4 h) was quenched with an anti–Alexa Fluor 488 Ab [(B), 1 h, n = 8 and 4 h, n = 3]. The uptake
of [MTTE]3-AF488 and [ETTM]3-AF488 by monocytes [(C), n = 9] and by blood-derived DCs [(E), n = 2]. The uptake pattern by monocytes of [MTTE]3-
AF488 and [ETTM]3-AF488 in a titration [(D), n = 1]. The data were analyzed with the Friedman test with Dunn correction (A) or the Wilcoxon signed-
rank test (B and C). The lines represent the mean. **p , 0.01.
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epitope QYIKANSKFIGITEL (30). It remains to be elucidated if
the reason for the universal anti-MTTE response is because the
T cell epitope is in proximity of the B cell epitope in the native
protein.
In a clinical setting, patients might benefit from a tetanus
vaccination prior to the initiation of the therapeutic conjugate
vaccine cycle, and as tetanus vaccination can have beneficial
effects on DC infiltration and activation at the vaccination site
(31), there is an opportunity for mutual benefits by smart clinical
trial design.
The Ab dependence of the conjugate was further confirmed by
the selective Ag uptake and T cell activation of conjugates with the
MTTE sequence and not the scrambled peptide (ETTM), which the
donors lack Abs against. In an attempt to study the route of uptake,
both FcgR and complement inhibitors were used. Whole IgG-
blocking Abs against FcgR and C1q turned out to be difficult to
FIGURE 4. Blocking C1q reduces the up-
take of [MTTE]3-AF488 by monocytes and
affects the IFN-g recall responses boosted by
[MTTE]3-NLV. The uptake of Alexa Fluor
488–labeled [MTTE]3-SLP ([MTTE]3-AF488)
by monocytes was blocked with EDTA (n = 5),
EGTA (n = 4), Compstatin (n = 3) (A), or a
C1q-blocking peptide (n = 4) (C). The block-
ing agents were preincubated for 10 min be-
fore the addition of [MTTE]3-AF488 to blood
from healthy donors in a circulating blood loop
assay. After 1 h of incubation, aliquots were
harvested and stained for blood monocytes
(CD14+ and CD192). The percentage of total
uptake was calculated by subtracting the
background (medium) mean fluorescence in-
tensity (MFI) (AF488) followed by (MFI of
block/MFI of [MTTE]3-AF488) 3 100 (A and
C). The blocking agents were preincubated for
10 min before [MTTE]3-NLV was added to
whole blood from HLA-A*0201+ and CMV+
healthy donors. After 2 h, Brefeldin A
was added, and after a total of 6 h, aliquots
were harvested and stained for T cell
markers, tetramer HLA-A*0201 CMV pp65
(NLVPMVATV), and intracellular IFN-g
and analyzed with flow cytometry. The
percentage of total recall response was
calculated by dividing (percentage of IFN-g
of block with percentage of IFN-g of
[MTTE]3-NLV) 3 100 [(B) and (D), n = 1].
The data were analyzed with the Wilcoxon
signed-rank test. The lines represent the
mean. *p , 0.05, **p , 0.01.
FIGURE 5. Healthy individuals have circulating IgG, but not IgM, Abs against the MTTE peptide. Antitetanus IgG titers of TetaQuin were determined
by an in-house ELISA using plates coated with TTd and the detection Abs: polyclonal anti-human IgG and isotype-specific HRP-conjugated Abs [(A),
repeated two times with similar results]. The presence of anti-MTTE IgG and IgM in plasma from blood loop donors was determined by coating strep-
tavidin plates with either MTTE-biotin or ETTM-biotin, and the IgG Abs were detected by a polyclonal anti-human IgG HRP-conjugated Ab [(B), n = 10]
or anti-human IgM HRP-conjugated Ab [(B), n = 9]. The data were analyzed with the Wilcoxon signed-rank test. The lines represent the mean. **p, 0.01.
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use in a system with intact complement due to their Ab-dependent
cell–mediated cytotoxicity/complement-dependent cytotoxicity–
promoting effect in the blood assay when the Abs cover circu-
lating cells. By the use of alternative complement blockers, we
could identify a role of the CP in conjugate uptake as both EDTA
(blocks AP and CP) and EGTA (blocks CP) affected uptake (23).
Additionally, EDTA and EGTA blocked the recall responses
induced by the [MTTE]3-NLV conjugate. However, EDTA
and EGTA influence several Mg2+- and Ca2+-dependent cellular
functions and therefore do not exclusively implicate the CP as the
route of uptake. The CP component C1q was shown to be es-
sential, rather than FcgR, for the uptake and cross-presentation of
OVA–Ab complexes in mice (24, 25). In this study, the uptake of
both OVA and [MTTE]3-AF488 by human monocytes were found
partly dependent on C1q rather than the C3-specific inhibitor
Compstatin. Consistently, recall responses were blocked by the
C1q inhibitor but not Compstatin. A role of C1q in conjugate
uptake and induction of recall responses is consistent with its
FIGURE 6. A standard tetanus booster vaccination elevates anti-MTTE IgG1 levels in plasma and enhances IFN-g recall responses of NLV-specific
CD8+ T cells in response to [MTTE]3-NLV. The anti-MTTE IgG and IgM levels in plasma pre- and posttetanus booster vaccination were determined in an
in-house ELISA where streptavidin plates were coated with MTTE-biotin (or ETTM-biotin) and the Abs were detected with a polyclonal anti-IgG,
polyclonal anti-IgM, or IgG isotype-specific HRP-conjugated Abs [(A), mean, n = 6 and (B), n = 6]. The peptide-conjugate [MTTE]3-NLV was incubated in
whole blood from HLA-A*0201+ and CMV+ healthy donors (pre- and posttetanus booster vaccination) in a circulating blood loop assay. After 2 h,
Brefeldin Awas added, and after a total of 6 h, aliquots were harvested and stained for T cell markers, tetramer HLA-A*0201 CMV pp65 (NLVPMVATV),
and intracellular IFN-g and TNF-a and analyzed with flow cytometry [(C), n = 2]. The data were analyzed with a two-way ANOVA. *p, 0.05, **p, 0.01.
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ability to bind human IgG1 (32), which was the main donor anti-
MTTE IgG isotype detected. Additionally, the enhanced recall
responses by mouse anti-MTTE IgG2a can be explained by its
ability to bind human C1q (33, 34). However, after the tetanus
vaccination, mIgG2a and mIgG1 specific for the MTTE reduced
the recall response, suggesting a competition with circulating
human Abs of which the murine with higher affinity wins. The
reduction of recall response could be a result of redirecting the
uptake to other cell types or simply an effect on uptake via Fc
receptors and/or complement fixation. Especially, mIgG1 is likely
to block the uptake, considering its low affinity for both human
FcgR (35) and C1q (33, 34); however, it is still unclear how mouse
IgG2a can have a dual role in this. C1q expression, or presence, on
the cell surface of monocytes (36, 37) can explain why blood
monocytes, but not B cells or granulocytes, take up the conjugate.
The maturation of monocyte-derived DCs (38) when cultured on
immobilized C1q, which mimics C1q cross-linking upon IC
binding, still supports this strategy as one with adjuvant potential,
despite that FcɣR does not appear involved in Ag uptake in human
whole blood.
In summary, our strategy of targeting Ags via Ag–Ab complexes
may improve T cell recall activation in humans if the responses
mimic the ex vivo responses to CMV and influenza that are
demonstrated in this study. As the blood loop assay measures
recall T cell responses, it will also be of importance to study
priming of naive T cells ahead. Clinically, most peptides are given
as intradermal or i.m. injections; the optimal administration of our
drug conjugate and the requirement of prevaccinated patients with
tetanus vaccination remains to be investigated. Lastly, the data in
this study supports the use of a selected B cell epitope as a carrier
peptide for Ag material into DCs to improve Ag presentation and
T cell activation.
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